Skip to main content
. 2016 Oct 19;102(3):600–609. doi: 10.3324/haematol.2016.147132

Figure 2.

Figure 2.

CD34+ cells in the peripheral blood in 20 subjects who received both doses of plerixafor. Individual subject plots with each line connecting the same subject at both dose levels representing the peak CD34+ peripheral blood count, CD34+ AUC over 24 h, CD34+ count 24 h after plerixafor administration, and time to peak CD34+ count.